Literature DB >> 21268124

MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese.

Jing Dong1, Binhui Ren, Zhibin Hu, Jiaping Chen, Lingmin Hu, Juncheng Dai, Guangfu Jin, Lin Xu, Hongbing Shen.   

Abstract

Murine double minute 2 (MDM2) is a negative regulator of the tumor suppressor gene p53. Single nucleotide polymorphisms in MDM2 and p53 can affect patient's response to chemotherapy as well as overall survival of many cancers. This study aimed to assess the associations between polymorphisms in MDM2 and p53 and survival of non-small cell lung cancer (NSCLC) patients in Chinese. We selected and genotyped both potentially functional SNPs and tagging SNPs in MDM2 and p53 using Illumina Golden Gate platform in a cohort of 568 NSCLC patients. Associations between genotypes and NSCLC median survival time (MST) were assessed using the Kaplan-Meier method. Cox proportional hazard models were performed with the adjustment for age, stage, smoking, histology, surgical operation, and chemo- or radiotherapy status. We found that the MDM2 SNP309 (rs2279744) GT/TT genotypes were associated with a significantly worse survival (MST: 23.0 mo for GT/TT vs. 33.0 mo for GG; log-rank P = 0.028). In the multivariate Cox regression analyses, the MDM2 SNP309GT/TT genotypes were associated with a 1.42-fold [HR = 1.42, 95% confidence interval (CI), 1.09-1.84] increased risk of death of NSCLC, compared with SNP309GG genotype. MDM2 SNP309 may be used as one of the candidate biomarkers to predict NSCLC survival.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21268124     DOI: 10.1002/mc.20727

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  10 in total

Review 1.  Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer.

Authors:  Shanbeh Zienolddiny; Vidar Skaug
Journal:  Lung Cancer (Auckl)       Date:  2011-12-29

2.  MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer.

Authors:  Bríd M Ryan; Kara M Calhoun; Sharon R Pine; Elise D Bowman; Ana I Robles; Stefan Ambs; Curtis C Harris
Journal:  Int J Cancer       Date:  2012-04-27       Impact factor: 7.396

3.  Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.

Authors:  Datong Zheng; Yanping Chen; Caijie Gao; Yongyue Wei; Guochun Cao; Nan Lu; Yayi Hou; Xiuqin Jiang; Jianjun Wang
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

4.  Single-nucleotide polymorphism (c.309T>G) in the MDM2 gene and lung cancer risk.

Authors:  Yasuaki Enokida; Kimihiro Shimizu; Seiichi Kakegawa; Jun Atsumi; Yoshiaki Takase; Yohei Miyamae; Toshiteru Nagashima; Yoichi Ohtaki; Kyoichi Kaira; Noriaki Sunaga; Noriko Yanagitani; Reiko Yoshino; Katsuhiko Tsunekawa; Hitoshi Igai; Mitsuhiro Kamiyoshihara; Kengo Usui; Alexander Lezhava; Yoshio Tomizawa; Toshihisa Ishikawa; Masami Murakami; Yoshihide Hayashizaki; Izumi Takeyoshi
Journal:  Biomed Rep       Date:  2014-06-26

5.  Individual and combined effect of TP53, MDM2, MDM4, MTHFR, CCR5, and CASP8 gene polymorphisms in lung cancer.

Authors:  Ausra Stumbryte; Zivile Gudleviciene; Gabrielis Kundrotas; Daiva Dabkeviciene; Agne Kunickaite; Saulius Cicenas
Journal:  Oncotarget       Date:  2017-11-29

6.  Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls.

Authors:  Wenlei Zhuo; Liang Zhang; Bo Zhu; Junjun Ling; Zhengtang Chen
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

7.  MDM2 SNP309 polymorphism is associated with lung cancer risk in women: A meta-analysis using METAGEN.

Authors:  Wenwu He; Jianxiong Long; Lei Xian; Feng Pang; Li Su; Shixiu Wei; Bo Wei; Yanling Hu
Journal:  Exp Ther Med       Date:  2012-07-18       Impact factor: 2.447

8.  MDM2 polymorphism associated with the development of cervical lesions in women infected with Human papillomavirus and using of oral contraceptives.

Authors:  Carolina Mm Amaral; Katerina Cetkovská; Ana Pad Gurgel; Marcus V Cardoso; Bárbara S Chagas; Sérgio Sl Paiva Júnior; Rita de Cássia Pereira de Lima; Jacinto C Silva-Neto; Luiz Af Silva; Maria Tc Muniz; Valdir Q Balbino; Antonio C Freitas
Journal:  Infect Agent Cancer       Date:  2014-07-18       Impact factor: 2.965

9.  Prognostic potential of the MDM2 309T>G polymorphism in stage I lung adenocarcinoma.

Authors:  Yasuaki Enokida; Kimihiro Shimizu; Jun Atsumi; Seiichi Kakegawa; Yoshiaki Takase; Kyoichi Kaira; Hideaki Yashima; Takuya Araki; Seshiru Nakazawa; Yoichi Ohtaki; Toshiteru Nagashima; Lezhava Alexander; Kengo Usui; Toshihisa Ishikawa; Yoshihide Hayashizaki; Izumi Takeyoshi
Journal:  Cancer Med       Date:  2016-05-26       Impact factor: 4.452

10.  Pharmacogenetic Association between XRCC1 Polymorphisms and Response to Platinum-Based Chemotherapy in Asian Patients with NSCLC: A Meta-Analysis.

Authors:  Ningning Zhang; Yushu Ouyang; Jianlan Chang; Ping Liu; Xiangyang Tian; Junyan Yu
Journal:  Biomed Res Int       Date:  2020-10-22       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.